» Articles » PMID: 17629734

Association Between BanI Genotype and Increased Phospholipase A2 Activity in Schizophrenia

Overview
Specialties Neurology
Psychiatry
Date 2007 Jul 17
PMID 17629734
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Phospholipases A2 (PLA2) are a family of key enzymes in the metabolism of membrane phospholipids. Several studies reported on increased blood and brain PLA2 activity in schizophrenia, which suggest a disordered phospholipid metabolism in the disease. In addition, a genetic variant of a cytosolic PLA2 gene has been reported to be associated with schizophrenia. These data indicate that variants of PLA2 encoding genes are plausible candidates for increasing the susceptibility for schizophrenia. In this study, we investigated a possible association between PLA2 activity in platelets and a polymorphic site for BanI in the PLA2 (group 4A) gene on chromosome 1q25. Seventy-five schizophrenic patients (DSM-IV) and 68 healthy controls were recruited and the PCR assays were performed. A radioenzymatic assay for the cytosolic PLA2 activity in platelets was used. The allele A2 and the genotype A2A2 were more frequent in schizophrenic patients than in controls (p<0.005 and p<0.05 respectively). When we assorted the subjects according to their genotypes, we found that PLA2 activity was significantly higher in patients with the A2A2 genotype (29.6+/-5.1 pMol/mg protein/min) than in those with the A1A2 (20.8+/-3.6 pMol/mg protein/min, p<0.001) or A1A1 genotype (15.9+/-5.1 pMol/mg protein/min, p<0.001). Also in controls, carriers of the A2 allele (A1A2 and A2A2) had higher PLA2 activity than the A1A1 group (p=0.004 for both). Our data suggest an association between BanI genotype and PLA2G4A activity in platelets and that the presence of the allele A2 may increase risk for schizophrenia through an increment of PLA2 activity.

Citing Articles

Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis.

Susai S, Healy C, Mongan D, Heurich M, Byrne J, Cannon M Transl Psychiatry. 2022; 12(1):454.

PMID: 36307392 PMC: 9616837. DOI: 10.1038/s41398-022-02217-0.


Impaired Membrane Lipid Homeostasis in Schizophrenia.

Li M, Gao Y, Wang D, Hu X, Jiang J, Qing Y Schizophr Bull. 2022; 48(5):1125-1135.

PMID: 35751100 PMC: 9434453. DOI: 10.1093/schbul/sbac011.


Inflammation and JNK's Role in Niacin-GPR109A Diminished Flushed Effect in Microglial and Neuronal Cells With Relevance to Schizophrenia.

Ansarey S Front Psychiatry. 2021; 12:771144.

PMID: 34916973 PMC: 8668869. DOI: 10.3389/fpsyt.2021.771144.


Acupuncture therapy protects PCOS patients with diabetes by regulating miR-32-3p/PLA2G4A pathway.

Wu J, Chen X Am J Transl Res. 2021; 13(8):8819-8832.

PMID: 34539997 PMC: 8430091.


Increased PLA activity in individuals at ultra-high risk for psychosis.

Talib L, Costa A, Joaquim H, Pereira C, van de Bilt M, Loch A Eur Arch Psychiatry Clin Neurosci. 2021; 271(8):1593-1599.

PMID: 33677687 DOI: 10.1007/s00406-021-01246-y.


References
1.
Gattaz W, Schmitt A, Maras A . Increased platelet phospholipase A2 activity in schizophrenia. Schizophr Res. 1995; 16(1):1-6. DOI: 10.1016/0920-9964(94)00060-l. View

2.
Turetsky B, Calkins M, Light G, Olincy A, Radant A, Swerdlow N . Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull. 2006; 33(1):69-94. PMC: 2632291. DOI: 10.1093/schbul/sbl060. View

3.
Pettegrew J, Keshavan M, Panchalingam K, Strychor S, Kaplan D, Tretta M . Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch Gen Psychiatry. 1991; 48(6):563-8. DOI: 10.1001/archpsyc.1991.01810300075011. View

4.
Gattaz W, Kollisch M, Thuren T, Virtanen J, Kinnunen P . Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy. Biol Psychiatry. 1987; 22(4):421-6. DOI: 10.1016/0006-3223(87)90164-8. View

5.
Law M, Cotton R, Berger G . The role of phospholipases A2 in schizophrenia. Mol Psychiatry. 2006; 11(6):547-56. DOI: 10.1038/sj.mp.4001819. View